

# Request For Proposal

*Pfizer Global Medical Grants* recently announced a request for proposal. Please review the criteria below and let us know if you are interested in pursuing this opportunity.

**Company:** Pfizer

**Area of Opportunity:** Oncology - Biosimilars

**Application Due Date:** September 9, 2020

**Link to full RFP:** [Adoption of Biosimilars in Oncology](#)

If you plan to apply, please let us know by completing the **OCR [Intent to Apply](#)** form.

**Specific Area of Interest:** The intent of the RFP is to encourage organizations to submit letters of intent (LOIs) describing concepts and ideas that improve the safe and efficient adoption or utilization of biosimilars in oncology. Emphasis is placed on adding value to the oncology care model through safe and effective use of biosimilars as well as the sustainability and broad applicability across university and community-based practices. Proposals that directly measure increases in biosimilar use or improve safety, value and efficiency in oncology practices will be prioritized.

Requirements:

<b>Clinical Area:</b>	Oncology
<b>Applicant Eligibility Criteria:</b>	<ul style="list-style-type: none"> <li>● Restricted to US institutions</li> <li>● Academic and Community Centers (Principal Investigators {PIs} from Academic Centers are encouraged to include a co-investigator from the community)</li> <li>● Patient Advocacy Groups</li> <li>● Open to any type of care delivery system with the exception small, physician-owned group practices</li> <li>● Health care professional organizations and other organizations with a mission related to health care improvement</li> </ul>
<b>Expected Approximate Monetary Range of Grant Applications:</b>	<p>Individual projects requesting up to \$250,000 (direct and indirect costs) will be considered; smaller, lower-cost projects are strongly encouraged.</p> <p>The maximum indirect (overhead) rate is 28% and must be included in the total grant request amount.</p> <p>The total funding available for this RFP is \$1.5 million.</p> <p>Applicants are required to disclose additional sources of funding for this project and demonstrate that funding does not overlap.</p>

Requirements:

<b>Estimated Key Dates:</b>	<p>LOI Deadline: <b>September 9, 2020</b> Please note the deadline is 11:59pm Eastern Time (New York, GMT -5).</p> <p>Anticipated LOI Notification Date: <b>October 28, 2020</b> Full Proposal Deadline: <b>*December 9, 2020</b> *Only accepted LOIs will be invited to submit full proposals. Please note the deadline is 11:59pm Eastern Time (New York, GMT -5).</p> <p>Anticipated Full Proposal Notification Date: <b>February 10, 2021</b></p> <p>Grants distributed following execution of fully signed Letter of Agreement</p> <p>Period of Performance: <b>12 months with the possibility of one 12 month no cost extension (requires approval)</b></p>
<b>How to Submit:</b>	<p>Please go to <a href="http://www.cybergrants.com/pfizer/loi">www.cybergrants.com/pfizer/loi</a> and sign in. First-time users should click "REGISTER NOW".</p> <p>Select the following Competitive Grant Program Name: <b>2020 Oncology NCCN Pfizer Biosimilars Project</b></p> <p>Select the following Area of Interest: <b>Oncology - Biosimilars</b></p> <p>Requirements for submission: Complete all required sections of the online application referring to the guide included in the Appendix</p> <p>If you encounter any technical difficulties with the website, please click the "Need Support?" link at the bottom of the page.</p> <p><b>IMPORTANT:</b> Be advised applications submitted through the wrong application type and/or submitted after the due date will not be reviewed by the committee.</p>

Emory Corporate Relations Contact: Gayathri Srinivasan – 404-210-3109 – [corporate@emory.edu](mailto:corporate@emory.edu)  
1762 Clifton Road · Suite 3400 · Atlanta, GA 30322  
[Giving.Emory.edu/CorporateRelations](http://Giving.Emory.edu/CorporateRelations)